
Urticaria as a Systemic Disease
All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten ZuberbierShow Notes
In this episode of the Global Allergy and Asthma Excellence Network UCARE Podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Marta Ferrer from Spain about an important question: Is chronic spontaneous urticaria (CSU) only a skin disease, or is it a systemic inflammatory condition? Together, they discuss emerging evidence showing that urticaria affects far more than the skin and how this should influence patient management.
They discuss: 🔹 Why is CSU increasingly considered a systemic inflammatory disease? 🔹 Which inflammatory biomarkers are linked to disease severity? 🔹 When should treatment be escalated beyond antihistamines? 🔹 How can biomarkers help personalize therapy? 🔹 Why are patient-reported outcomes and real-world data so important? 🔹 How do comorbidities influence treatment decisions?
The discussion highlights the importance of early disease control, individualized treatment strategies, and understanding that chronic urticaria often extends beyond wheals and itch alone.
Key Learnings from the Episode: Chronic spontaneous urticaria is more than a skin disease. Patients often experience fatigue, sleep disturbances, and systemic symptoms. Inflammatory biomarkers such as CRP, D-dimer, and serum amyloid A correlate with disease activity. If antihistamines fail within a few weeks, treatment escalation should be considered. Modern therapies should aim for complete disease control as early as possible. Patient comorbidities can help guide individualized treatment choices. Real-world data from registries and digital tools are improving understanding of CSU. Personalized treatment strategies are becoming increasingly important in urticaria care.
Chapters: 00:00 Introduction 01:41 Is Urticaria a Systemic Disease? 03:38 Inflammatory Markers and Diagnostics in Chronic Urticaria 06:51 When Antihistamines Are Not Enough 09:35 Choosing Second-Line Treatment 11:19 Shared Decision-Making: Omalizumab, Remibrutinib or Dupilumab? 13:37 D-Dimer in Urticaria: Inflammation, Not Thrombosis 16:09 Real-World Evidence and New Treatment Options 17:22 Neutrophilic Urticaria and Difficult-to-Treat Patients 19:59 Comorbidities as a Guide to Treatment Choice
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH
More from All Things Urticaria – Learning about urticaria with Prof. Dr. Torsten Zuberbier
In this episode of the UCARE Global Allergy and Asthma Excellence Network podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Angelo Valerio Marzano from Milan about urticarial vasculitis and its challenging differential diagnoses. They explore how clinicians can distinguish urticarial vasculitis from chronic urticaria and other dermatological or systemic conditions and discuss practical approaches to diagnosis and treatment.
In this episode of the UCARE Global Allergy and Asthma Excellence Network (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier speaks with Prof. Akio Tanaka from Hiroshima University, Japan, about an important question many patients ask: how long will chronic urticaria last, and can treatment influence the course of the disease? They discuss disease modification, symptom control, and future research directions in urticaria management.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Hermenio Lima discuss the growing role of artificial intelligence (AI) in medicine and how it may influence urticaria care, research, and patient management in the future.
In this episode of the UCARE GA²LEN (Global Allergy and Asthma Excellence Network) podcast on Urticaria, Prof. Torsten Zuberbier and Prof. Maia Gotua discuss the role of infections in acute and chronic urticaria. They explore how infections can trigger, mimic, or worsen symptoms—and why careful clinical evaluation is key.
In this episode of “All Things Urticaria” — a podcast from UCARE, the Global Allergy and Asthma Excellence Network — Prof. Torsten Zuberbier and Prof. Ana Giménez-Arnau discuss the newly released international urticaria guidelines. Developed with contributions from more than 100 societies and hundreds of experts worldwide, these guidelines represent a major step forward in the management of chronic spontaneous urticaria (CSU).